meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA) 1
es-BC - HER2 positive - (neo)adjuvant (NA) 4
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1) 5
la/mBC - HER2 positive - 2nd Line (L2) 13

immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs paclitaxel followed by doxorubicin plus cyclophosphamide

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -